Article
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.
Nature - 26 Feb 2015
Wong Terrence N, Ramsingh Giridharan, Young Andrew L, Miller Christopher A, Touma Waseem, Welch John S, Lamprecht Tamara L, Shen Dong, Hundal Jasreet, Fulton Robert S, Heath Sharon, Baty Jack D, Klco Jeffery M, Ding Li, Mardis Elaine R, Westervelt Peter, DiPersio John F, Walter Matthew J, Graubert Timothy A, Ley Timothy J, Druley Todd, Link Daniel C, Wilson Richard K
Abstract excerpt
Therapy-related acute myeloid leukaemia (t-AML) and therapy-related myelodysplastic syndrome (t-MDS) are well-recognized complications of cytotoxic chemotherapy and/or radiotherapy. There are several features that distinguish t-AML from de novo AML, including a higher incidence of TP53 mutations, abnormalities of chromosomes 5 or 7, complex cytogenetics and a reduced response to chemotherapy. However, it is not...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.